These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11698228)

  • 21. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
    Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
    AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.
    Moyle GJ; Baldwin C; Langroudi B; Mandalia S; Gazzard BG
    J Acquir Immune Defic Syndr; 2003 May; 33(1):22-8. PubMed ID: 12792351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
    Barreiro P; García-Benayas T; Soriano V; Gallant J
    AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
    Cozzi-Lepri A; De Luca A; Phillips AN; Bongiovanni M; Di Giambenedetto S; Mena M; Moioli MC; Arlotti M; Sighinolfi L; Narciso P; Lichtner M; Cauda R; Monforte Ad; ; ;
    J Infect Dis; 2006 Jul; 194(1):20-8. PubMed ID: 16741878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
    Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
    Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
    Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
    HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on HAART: switch maintenance therapy.
    Leen CL
    Int J STD AIDS; 2003 Sep; 14(9):577-82. PubMed ID: 14511491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using abacavir to avoid lipid problems.
    TreatmentUpdate; 2002 Mar; 14(3):6. PubMed ID: 12033190
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.